slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 63,931-63,960
Pages 3,679
Rows per page 30
Component
63,931-63,960 of 110,355
05
Bionomics | Investor Presentation Deck | 16 slidesBionomics | Investor Presentation Deck | 16 slides · Bionomics
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
The slide combines a bar chart for revenue projections and a segmented pie/fan chart for patient population sizing.Bionomics | Investor Presentation Deck | 16 slides · Bionomics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
09
The slide uses a split-layout: left side lists clinical symptoms/causes, right side details functional impact on life domains.Bionomics | Investor Presentation Deck | 16 slides · Bionomics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
10
The slide uses a combination of a bar chart for revenue projections and a layered pie/segmentation graphic for patient population sizing.Bionomics | Investor Presentation Deck | 16 slides · Bionomics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
15
The slide uses a vertical timeline structure to present key corporate and clinical milestones.Bionomics | Investor Presentation Deck | 16 slides · Bionomics
Pitch deck Investor relations 1 hit
09
Includes a list of key metrics and a bottom banner highlighting broader societal impact.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Problem StatementLoop · Logic Chain1 hit
10
The timeline uses a split-level design to accommodate many events over a long period.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Solution OverviewLoop · Logic Chain1 hit
13
BioNTech | Investor Day Presentation Deck | 156 slidesBioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Solution OverviewLoop · Logic Chain1 hit
19
The slide outlines a two-stage process: Mutation discovery (sequencing, analysis, identification, validation) followed by Immunogenicity testing (peptide immunization and ELISPOT).BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Solution OverviewLoop · Logic Chain1 hit
20
The slide uses a biological process diagram on the left and a scatter plot of mutation burden across cancer types on the right.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Solution OverviewLoop · Logic Chain1 hit
23
The slide highlights the transition from automated computational prediction to human expert verification.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Loop · Golden Circle1 hit
24
The slide highlights the manufacturing process for personalized cancer vaccines, specifically focusing on the mRNA backbone and neoantigen integration.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Loop · Golden Circle1 hit
25
Source: Lang F, et al. Nature Rev Drug Discov 2022; 21:261-282.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Loop · Golden Circle1 hit
26
The chart uses a broken y-axis to show high-frequency outliers alongside the long tail of low-frequency targets.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Loop · Golden Circle1 hit
34
Includes schematic of lipid bilayer structure, RNA-lipoplex screening process, and bioluminescence imaging data.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations 1 hit
35
Includes chemical structure of PSAR-LNP components and a line chart comparing in vivo expression profiles.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations 1 hit
39
The slide uses biological diagrams to illustrate the process of T-cell recognition and tumor cell interaction, alongside a list of key criteria for neoantigen prediction.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations 1 hit
40
The slide uses a funnel to represent the reduction of candidates from exome variations to validated immunogenic neo-epitopes.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations 1 hit
42
The ROC curve shows the new model (blue) consistently outperforming the baseline NetMHCpan 4.1 EL (orange).BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations 1 hit
44
The slide shows structural models of spike proteins (Wuhan, Beta, Omicron) alongside scatter plots correlating epitope alteration/semantic change/immune escape scores with pVNT50 reduction and ACE2 binding affinity.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations 1 hit
61
The slide uses a three-column layout to present the problem, with a footer section listing the company's solutions.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Market Opportunity1 hit
65
The slide uses a before-after framing to contrast efficacy and safety data.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Market Opportunity1 hit
67
The table highlights that all tested Omicron-modified vaccines met the superiority criterion (lower bound of 95% CI for GMR > 1.0).BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Market Opportunity1 hit
70
The chart compares baseline (Prevax 1MPD) vs post-vaccination GMTs for various BNT162b2 and Bivalent formulations.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations Beat · Market Opportunity1 hit
72
BioNTech | Investor Day Presentation Deck | 156 slidesBioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations 1 hit
73
The chart illustrates the need for faster vaccine development cycles due to the rapid turnover of viral strains.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations 1 hit
75
The chart uses a highlighted box to focus on the Omicron period starting December 2021.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations 1 hit
77
Data shows neutralization titers for OMI and Bivalent vaccines against BA.1 and BA.4/5 variants.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations 1 hit
82
Slide 82 from a BioNTech presentation.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations 1 hit
84
The slide uses a three-column layout to frame the problem and the proposed solution.BioNTech | Investor Day Presentation Deck | 156 slides · BioNTech
Conference presentation Investor relations 1 hit